Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Exclusivity Review: Commission To Assess Impact On 'Skyrocketing' Drug Prices

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysis will consider effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines; European health ministers also pledge cooperation rein in what they see as the very high prices of some medicines.

You may also be interested in...



EU Report Probes Impact Of IP Incentives On R&D, Market Access

A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.

EU Report Probes Impact Of IP Incentives On R&D, Market Access

A report for the European Commission’s analysis of pharmaceutical IP incentives finds that the effective protection period has declined over 20 years, but delays to generic entry are still putting pressure on pharmaceutical spending.

Trenches, Silos And Circular Debates: European Health Forum Calls For Collaboration On IP And Medicines Access

A session on intellectual property and its effects on access to new medicines was the subject of heated debate at the recent European Health Forum Gastein conference, with proponents of strong IP protections locking horns with health activists over issues such as the link between IP and high prices.

Related Content

Topics

UsernamePublicRestriction

Register

PS079535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel